Overview
Biologic drugs are used to treat various life-threatening diseases with a variety of effects. These medicines, however, are also used for prevention of diseases. They have been developed through various research programs that span over decades. Many biologics have shown great potential in the field of medicine.
Global Oral Biologics Market is estimated to be valued at US$ 1,437.4 million in 2021 and is expected to exhibit a CAGR of 35.3% over the forecast period (2021-2028).
Request Here Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/989
Market: Drivers
Increasing incidences of diabetes is expected to propel growth of the global oral biologics market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.
Market: Opportunities
R&D of orally administered Glucagon-like Peptide 1 (GLP-1) Receptor Agonist is expected to offer lucrative growth opportunities for players in the global oral biologics market. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, which is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in the form of a pill.
Market: Recent Developments
Major players operating in the global oral biologics market are focused on adopting partnership strategies to expand their product portfolio. For instance, in April 2018, Emisphere Technologies, Inc. amended its license agreement with Novo Nordisk A/S for R&D of oral formulations of four classes of Novo Nordisk’s investigational molecules targeting major metabolic disorders. The agreement was earlier signed in October 2015 and gave Novo Nordisk the exclusive rights to develop potential product candidates in three molecule classes, and the non-exclusive right to develop potential product candidates in a fourth molecule class, using the Eligen Technology.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/989
Covid-19 Impact Analysis:
There has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions with the emergence of Covid-19. The pandemic has significantly spread in the Americas. In Brazil, from 3 January 2020 to 6:19pm CEST, 27 September 2021, there have been 21,343,304 confirmed cases of COVID-19 with 594,200 deaths, reported to WHO. As of 23 September 2021, a total of 216,763,268 vaccine doses have been administered. Various biologics such as tumor necrosis factor inhibitors, interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors used in the treatment of psoriasis have not been linked with increase in the risk of COVID-19 infection.
Key Takeaways:
The global oral biologics market is expected to exhibit a CAGR of 35.3 % over the forecast period, owing to R&D of oral biologics. For instance, in 2018, Amgen Inc. partnered with Entera Bio for R&D of oral formulations of biologics.
Competitive Landscape
Major players operating in the global oral biologics market include, Allena Pharmaceuticals, Inc., AbbVie Inc., Biocon Limited, Chiasma, Inc., Entera Bio Ltd., Enteris BioPharma, Inc., Novo Nordisk A/S, Oramed Pharmaceuticals, Inc., and Rani Therapeutics.
Reasons to Purchase this Report
• Current and future of global oral biologics market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Pipeline Analysis
- PEST Analysis
- Adherence of Patients- Injectable Biologics
- Regulatory Scenario
- Limitations of Injectable Biologics
- Epidemiology
- Mechanism of Action- Pill Technology
- Merger, Acquisitions, And Collaborations Scenario
- Market Dynamics
- Global Oral Biologics Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Overall Impact on Healthcare Industry
- COVID-19 Impact on Clinical Trials
- Global Oral Biologics Market, By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Hormone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Recombinant Enzyme
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Guanylate Cyclase-C Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Somatostatin Analogue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Oral Biologics Market, By Disease Indication, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Hyperoxaluria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Acromegaly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Oral Biologics Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Oral Biologics Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Novo Nordisk A/S *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biocon Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Oramed Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Rani Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Entera Bio Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Enteris BioPharma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Chiasma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Allena Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novo Nordisk A/S *
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837